Combined Intravitreal Bevacizumab and Photodynamic Therapy for Retinal Angiomatous Proliferation

Masaaki Saito, Chieko Shiragami, Fumio Shiraga, Dai Nagayama, Tomohiro Iida

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Purpose: To clarify the efficiency of combined therapy with intravitreal bevacizumab injections and photodynamic therapy (PDT) in patients with retinal angiomatous proliferation (RAP). Design: Retrospective, observational, consecutive case series. Methods: We retrospectively reviewed 11 consecutive eyes with RAP (10 patients; six men, four women) treated with intravitreal bevacizumab injection and PDT. Patients ranged in age from 63 to 89 years old (average, 79 years). No patients had undergone previous treatment, and patients were followed for at least six months. PDT was applied one or two days after the intravitreal bevacizumab (1.25 mg) injection. Results: The mean best-corrected visual acuity (BCVA) levels at baseline and one, three, and six months after treatment were 0.16, 0.27, 0.31, and 0.29, respectively. A significant improvement in the mean BCVA was observed one, three, and six months after intravitreal bevacizumab injection and PDT (P <.01). The mean improvement in BCVA six months from baseline was 2.64 lines. The BCVA at six months improved in six eyes (54.5%, improved by three lines or more) and was stable in five eyes (45.5%). No patient had a decrease in the BCVA of three or more lines during any six months. The central retinal thickness significantly decreased from 496 ± 189 μm to 175 ± 33 μm at six months (P <.001). No patients required retreatment during any six months. No complications such as severe vision loss, endophthalmitis, or systemic events developed. Conclusion: Combined intravitreal bevacizumab and PDT for RAP effectively maintained or improved VA and reduced or eliminated edema in the short-term.

Original languageEnglish
JournalAmerican Journal of Ophthalmology
Volume146
Issue number6
DOIs
Publication statusPublished - Dec 2008
Externally publishedYes

Fingerprint

Photochemotherapy
Visual Acuity
Intravitreal Injections
Retreatment
Endophthalmitis
Bevacizumab
Edema
Therapeutics
Injections

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Combined Intravitreal Bevacizumab and Photodynamic Therapy for Retinal Angiomatous Proliferation. / Saito, Masaaki; Shiragami, Chieko; Shiraga, Fumio; Nagayama, Dai; Iida, Tomohiro.

In: American Journal of Ophthalmology, Vol. 146, No. 6, 12.2008.

Research output: Contribution to journalArticle

Saito, Masaaki ; Shiragami, Chieko ; Shiraga, Fumio ; Nagayama, Dai ; Iida, Tomohiro. / Combined Intravitreal Bevacizumab and Photodynamic Therapy for Retinal Angiomatous Proliferation. In: American Journal of Ophthalmology. 2008 ; Vol. 146, No. 6.
@article{f4ee78924bc14a4a88b24e342b7cb2b4,
title = "Combined Intravitreal Bevacizumab and Photodynamic Therapy for Retinal Angiomatous Proliferation",
abstract = "Purpose: To clarify the efficiency of combined therapy with intravitreal bevacizumab injections and photodynamic therapy (PDT) in patients with retinal angiomatous proliferation (RAP). Design: Retrospective, observational, consecutive case series. Methods: We retrospectively reviewed 11 consecutive eyes with RAP (10 patients; six men, four women) treated with intravitreal bevacizumab injection and PDT. Patients ranged in age from 63 to 89 years old (average, 79 years). No patients had undergone previous treatment, and patients were followed for at least six months. PDT was applied one or two days after the intravitreal bevacizumab (1.25 mg) injection. Results: The mean best-corrected visual acuity (BCVA) levels at baseline and one, three, and six months after treatment were 0.16, 0.27, 0.31, and 0.29, respectively. A significant improvement in the mean BCVA was observed one, three, and six months after intravitreal bevacizumab injection and PDT (P <.01). The mean improvement in BCVA six months from baseline was 2.64 lines. The BCVA at six months improved in six eyes (54.5{\%}, improved by three lines or more) and was stable in five eyes (45.5{\%}). No patient had a decrease in the BCVA of three or more lines during any six months. The central retinal thickness significantly decreased from 496 ± 189 μm to 175 ± 33 μm at six months (P <.001). No patients required retreatment during any six months. No complications such as severe vision loss, endophthalmitis, or systemic events developed. Conclusion: Combined intravitreal bevacizumab and PDT for RAP effectively maintained or improved VA and reduced or eliminated edema in the short-term.",
author = "Masaaki Saito and Chieko Shiragami and Fumio Shiraga and Dai Nagayama and Tomohiro Iida",
year = "2008",
month = "12",
doi = "10.1016/j.ajo.2008.06.033",
language = "English",
volume = "146",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "6",

}

TY - JOUR

T1 - Combined Intravitreal Bevacizumab and Photodynamic Therapy for Retinal Angiomatous Proliferation

AU - Saito, Masaaki

AU - Shiragami, Chieko

AU - Shiraga, Fumio

AU - Nagayama, Dai

AU - Iida, Tomohiro

PY - 2008/12

Y1 - 2008/12

N2 - Purpose: To clarify the efficiency of combined therapy with intravitreal bevacizumab injections and photodynamic therapy (PDT) in patients with retinal angiomatous proliferation (RAP). Design: Retrospective, observational, consecutive case series. Methods: We retrospectively reviewed 11 consecutive eyes with RAP (10 patients; six men, four women) treated with intravitreal bevacizumab injection and PDT. Patients ranged in age from 63 to 89 years old (average, 79 years). No patients had undergone previous treatment, and patients were followed for at least six months. PDT was applied one or two days after the intravitreal bevacizumab (1.25 mg) injection. Results: The mean best-corrected visual acuity (BCVA) levels at baseline and one, three, and six months after treatment were 0.16, 0.27, 0.31, and 0.29, respectively. A significant improvement in the mean BCVA was observed one, three, and six months after intravitreal bevacizumab injection and PDT (P <.01). The mean improvement in BCVA six months from baseline was 2.64 lines. The BCVA at six months improved in six eyes (54.5%, improved by three lines or more) and was stable in five eyes (45.5%). No patient had a decrease in the BCVA of three or more lines during any six months. The central retinal thickness significantly decreased from 496 ± 189 μm to 175 ± 33 μm at six months (P <.001). No patients required retreatment during any six months. No complications such as severe vision loss, endophthalmitis, or systemic events developed. Conclusion: Combined intravitreal bevacizumab and PDT for RAP effectively maintained or improved VA and reduced or eliminated edema in the short-term.

AB - Purpose: To clarify the efficiency of combined therapy with intravitreal bevacizumab injections and photodynamic therapy (PDT) in patients with retinal angiomatous proliferation (RAP). Design: Retrospective, observational, consecutive case series. Methods: We retrospectively reviewed 11 consecutive eyes with RAP (10 patients; six men, four women) treated with intravitreal bevacizumab injection and PDT. Patients ranged in age from 63 to 89 years old (average, 79 years). No patients had undergone previous treatment, and patients were followed for at least six months. PDT was applied one or two days after the intravitreal bevacizumab (1.25 mg) injection. Results: The mean best-corrected visual acuity (BCVA) levels at baseline and one, three, and six months after treatment were 0.16, 0.27, 0.31, and 0.29, respectively. A significant improvement in the mean BCVA was observed one, three, and six months after intravitreal bevacizumab injection and PDT (P <.01). The mean improvement in BCVA six months from baseline was 2.64 lines. The BCVA at six months improved in six eyes (54.5%, improved by three lines or more) and was stable in five eyes (45.5%). No patient had a decrease in the BCVA of three or more lines during any six months. The central retinal thickness significantly decreased from 496 ± 189 μm to 175 ± 33 μm at six months (P <.001). No patients required retreatment during any six months. No complications such as severe vision loss, endophthalmitis, or systemic events developed. Conclusion: Combined intravitreal bevacizumab and PDT for RAP effectively maintained or improved VA and reduced or eliminated edema in the short-term.

UR - http://www.scopus.com/inward/record.url?scp=56249084202&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56249084202&partnerID=8YFLogxK

U2 - 10.1016/j.ajo.2008.06.033

DO - 10.1016/j.ajo.2008.06.033

M3 - Article

VL - 146

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 6

ER -